Theravance Biopharma Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Theravance Biopharma Stock Summary

Theravance Biopharma competes with Instil Bio, Achilles Therapeutics, NextCure, Assembly Biosciences, and Nuvation Bio. Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. Theravance Bio is traded on NASDAQ Exchange in the United States.

Theravance Biopharma Key Financial Ratios

Theravance Biopharma Key Balance Sheet Accounts

Theravance Biopharma Key Income Statement Accounts

Theravance Biopharma Key Cash Accounts

Theravance Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Theravance Biopharma's current stock value. Our valuation model uses many indicators to compare Theravance Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Theravance Biopharma competition to find correlations between indicators driving Theravance Biopharma's intrinsic value. More Info.Theravance Biopharma is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . As of now, Theravance Biopharma's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Theravance Biopharma's earnings, one of the primary drivers of an investment's value.

Theravance Biopharma Systematic Risk

Today, most investors in Theravance Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Theravance Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Theravance Biopharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Theravance Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Theravance Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Theravance Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Theravance Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Theravance Biopharma's daily price indicators and compare them against related drivers.

When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.